Research
CAR T-cell therapy shows promise for patients with lupus
The Brief
- Research presented at the annual meeting of the American College of Rheumatology (ACR Convergence) found CAR T-cell therapy is associated with consistent reductions in disease activity in patients with systemic lupus erythematosus.
- The source reports the association as consistent across the findings presented, but the available excerpt does not give trial size, follow-up length or comparison groups.
Why it matters
Lupus is a chronic autoimmune disease with limited options for patients whose disease does not respond to standard treatment, so consistent reductions in disease activity from CAR T-cell therapy are a signal worth tracking for rheumatology and cell therapy research.
Who’s affected
- patients with systemic lupus erythematosus
- rheumatologists
- researchers in cell therapy and autoimmune disease
- #car t-cell therapy
- #lupus
- #autoimmune disease
- #rheumatology
- #cell therapy
For patients with systemic lupus erythematosus (SLE), chimeric antigen receptor T-cell (CAR T-cell) therapy is associated with consistent reductions in disease activity, according to research presented at the annual meeting of the American College of Rheumatology (ACR Convergence…